Platinum-sensitive recurrence in ovarian cancer: The role of tumor microenvironment

Frontiers in Oncology

Volumn 3 SEP, Issue , 2013, Pages

  Chien, Jeremy ^a   Kuang, Rui ^b   Landen, Charles ^c   Shridhar, Viji ^d  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b University of Minnesota   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d MAYO CLINIC   (United States)

Author keywords

Cancer stem cell; Extracellular matrix; Ovarian cancer; Platinum resistance; Platinum sensitive recurrence

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CHLOROQUINE; CISPLATIN; COLLAGEN TYPE 6; CYCLIN E; DACTOLISIB; FIBRILLIN 1; HEPARIN; N (2, 3 DIHYDRO 7, 8 DIMETHOXYIMIDAZO [1, 2 C] QUINAZOLIN 5 YL) NICOTINAMIDE; N (2,3 DIHYDRO 7,8 DIMETHOXYIMIDAZO[1,2 C]QUINAZOLIN 5 YL)NICOTINAMIDE; PICTILISIB; PLATINUM; RAPAMYCIN; UNCLASSIFIED DRUG;

ARTICLE; AUTOPHAGY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STEM CELL; CELL ADHESION; CELL DIFFERENTIATION; CELL INTERACTION; CELL PROLIFERATION; COLORECTAL CANCER; DRUG SENSITIVITY; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; OVARY CANCER; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR MICROENVIRONMENT;

EID: 84888065590     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00251     Document Type: Article

References (37)

1. Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol (2006) 24:4699-707. doi:10.1200/JCO.2006.06.0913
2. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet (2003) 361:2099-106. doi:10.1016/S0140-6736(03)13718-X
3. Pfisterer J, Ledermann JA. Management of platinum-sensitive recurrent ovarian cancer. Semin Oncol (2006) 33:S12-6. doi:10.1053/j.seminoncol.2006.03.012
4. Banerjee S, Bookman M, Gore M. Systemic therapy for ovarian cancer, current treatment, recent advances, and unmet needs. In: Kaye S, Brown R, Gabra H, Gore M editors. Emerging Therapeutic Targets in Ovarian Cancer. London: Springer (2011). p. 1-34.
5. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene (2012) 31:1869-83. doi:10.1038/onc.2011.384
6. NCI. Defining therapy for recurrent platinum-sensitive ovarian cancer. NCI Cancer Bull (2008).Available from: http://www.cancer.gov/ncicancerbulletin/archive/2008/061008/page8
7. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer (2003) 3:502-16. doi:10.1038/nrc1123
8. Turner NC, Reis-Filho JS. Genetic heterogeneity and cancer drug resistance. Lancet Oncol (2012) 13:e178-85. doi:10.1016/S1470-2045(11)70335-7
9. Steg AD, Bevis KS, Katre AA, Ziebarth A, Dobbin ZC, Alvarez RD, et al. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res (2012) 18:869-81. doi:10.1158/1078-0432.CCR-11-2188
10. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian inhibiting substance responsiveness. Proc Natl Acad Sci U S A (2006) 103:11154-9. doi:10.1073/pnas.0603672103
11. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res (2008) 68:4311-20. doi:10.1158/0008-5472.CAN-08-0364
12. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer (2007) 7:834-46. doi:10.1038/nri2210
13. Kreso A, O'Brien CA, van Galen P, Gan OI, Notta F, Brown AM, et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science (2013) 339:543-8. doi:10.1126/science.1227670
14. Lu Z, Luo RZ, Lu Y, Zhang X, Yu Q, Khare S, et al. The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest (2008) 118:3917-29. doi:10.1172/JCI35512
15. Correia AL, Bissell MJ. The tumor microenvironment is a dominant force in multidrug resistance. Drug Resist Updat (2012) 15:39-49. doi:10.1016/j.drup.2012.01.006
16. Li L, Neaves WB. Normal stem cells and cancer stem cells: the niche matters. Cancer Res (2006) 66:4553-7. doi:10.1158/0008-5472.CAN-05-3986
17. Watt FM, Hogan BL. Out of Eden: stem cells and their niches. Science (2000) 287:1427-30. doi:10.1126/science.287.5457.1427
18. Scadden DT. The stem-cell niche as an entity of action. Nature (2006) 441:1075-9. doi:10.1038/nature04957
19. Barkan D, Green JE, Chambers AF. Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth. Eur J Cancer (2010) 46:1181-8. doi:10.1016/j.ejca.2010.02.027
20. Sherman-Baust CA, Weeraratna AT, Rangel LB, Pizer ES, Cho KR, Schwartz DR, et al. Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell (2003) 3:377-86. doi:10.1016/S1535-6108(03)00058-8
21. Sethi T, Rintoul RC, Moore SM, MacKinnon AC, Salter D, Choo C, et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med (1999) 5:662-8. doi:10.1038/9511
22. Helleman J, Jansen MP, Burger C, van der Burg ME, Berns EM. Integrated genomics of chemotherapy resistant ovarian cancer: a role for extracellular matrix, TGFbeta and regulating microRNAs. Int J Biochem Cell Biol (2010) 42:25-30. doi:10.1016/j.biocel.2009.10.016
23. Etemadmoghadam D, deFazio A, Beroukhim R, Mermel C, George J, Getz G, et al. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res (2009) 15:1417-27. doi:10.1158/1078-0432.CCR-08-1564
24. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature (2011) 474:609-15. doi:10.1038/nature10166
25. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res (2008) 14:5198-208. doi:10.1158/1078-0432.CCR-08-0196
26. Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res (2005) 65:10602-12. doi:10.1158/0008-5472.CAN-05-2240
27. Zhang W, Ota T, Shridhar V, Chien J, Wu B, Kuang R. Network-based survival analysis reveals subnetwork signatures for predicting outcomes of ovarian cancer treatment. PLoS Comput Biol (2013) 9(3):e1002975. doi:10.1371/journal.pcbi.1002975
28. Tremble P, Damsky CH, Werb Z. Components of the nuclear signaling cascade that regulate collagenase gene expression in response to integrin-derived signals. J Cell Biol (1995) 129:1707-20. doi:10.1083/jcb.129.6.1707
29. Muranen T, Selfors LM, Worster DT, Iwanicki MP, Song L, Morales FC, et al. Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell (2012) 21:227-39. doi:10.1016/j.ccr.2011.12.024
30. Dolberg DS, Bissell MJ. Inability of Rous sarcoma virus to cause sarcomas in the avian embryo. Nature (1984) 309:552-6. doi:10.1038/309552a0
31. Howlett AR, Carter VC, Martin GS, Bissell MJ. pp60v-src tyrosine kinase is expressed and active in sarcoma-free avian embryos microinjected with Rous sarcoma virus. Proc Natl Acad Sci U S A (1988) 85:7587-91. doi:10.1073/pnas.85.20.7587
32. Stoker AW, Hatier C, Bissell MJ. The embryonic environment strongly attenuates v-src oncogenesis in mesenchymal and epithelial tissues, but not in endothelia. J Cell Biol (1990) 111:217-28. doi:10.1083/jcb.111.1.217
33. Hendrix MJ, Seftor EA, Seftor RE, Kasemeier-Kulesa J, Kulesa PM, Postovit LM. Reprogramming metastatic tumour cells with embryonic microenvironments. Nat Rev Cancer (2007) 7:246-55. doi:10.1038/nrc2108
34. Topczewska JM, Postovit LM, Margaryan NV, Sam A, Hess AR, Wheaton WW, et al. Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness. Nat Med (2006) 12:925-32. doi:10.1038/nm1448
35. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood (1999) 93:1658-67.
36. Hazlehurst LA, Damiano JS, Buyuksal I, Pledger WJ, Dalton WS. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene (2000) 19:4319-27. doi:10.1038/sj.onc.1203782
37. Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med (2011) 17:1498-503. doi:10.1038/nm.2492